Company’s 36-month beta value is 1.66.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VCYT is 76.33M, and currently, short sellers hold a 4.06% ratio of that floaft. The average trading volume of VCYT on November 15, 2024 was 771.55K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VCYT) stock’s latest price update
The stock of Veracyte Inc (NASDAQ: VCYT) has decreased by -6.30 when compared to last closing price of 39.53. Despite this, the company has experienced a -0.80% fall in its stock price over the last five trading sessions. zacks.com reported 2024-11-07 that VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
VCYT’s Market Performance
Veracyte Inc (VCYT) has seen a -0.80% fall in stock performance for the week, with a 6.68% gain in the past month and a 12.75% surge in the past quarter. The volatility ratio for the week is 4.76%, and the volatility levels for the past 30 days are at 3.94% for VCYT. The simple moving average for the past 20 days is 5.08% for VCYT’s stock, with a 42.50% simple moving average for the past 200 days.
Analysts’ Opinion of VCYT
Many brokerage firms have already submitted their reports for VCYT stocks, with UBS repeating the rating for VCYT by listing it as a “Buy.” The predicted price for VCYT in the upcoming period, according to UBS is $43 based on the research report published on October 16, 2024 of the current year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see VCYT reach a price target of $40. The rating they have provided for VCYT stocks is “Buy” according to the report published on October 10th, 2024.
Needham gave a rating of “Buy” to VCYT, setting the target price at $33 in the report published on February 23rd of the current year.
VCYT Trading at 9.21% from the 50-Day Moving Average
After a stumble in the market that brought VCYT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.60% of loss for the given period.
Volatility was left at 3.94%, however, over the last 30 days, the volatility rate increased by 4.76%, as shares surge +7.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.42% upper at present.
During the last 5 trading sessions, VCYT fell by -0.80%, which changed the moving average for the period of 200-days by +48.04% in comparison to the 20-day moving average, which settled at $35.25. In addition, Veracyte Inc saw 34.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VCYT starting from Chambers Rebecca, who sale 15,275 shares at the price of $38.34 back on Nov 12 ’24. After this action, Chambers Rebecca now owns 124,501 shares of Veracyte Inc, valued at $585,663 using the latest closing price.
EPSTEIN ROBERT S, the Director of Veracyte Inc, sale 15,000 shares at $38.32 during a trade that took place back on Nov 12 ’24, which means that EPSTEIN ROBERT S is holding 44,598 shares at $574,830 based on the most recent closing price.
Stock Fundamentals for VCYT
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.65 for the gross margin
The net margin for Veracyte Inc stands at -0.02. The total capital return value is set at 0.01. Equity return is now at value -0.83, with -0.77 for asset returns.
Currently, EBITDA for the company is -49.41 million with net debt to EBITDA at -93.9. When we switch over and look at the enterprise to sales, we see a ratio of 6.15. The receivables turnover for the company is 8.71for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.08.
Conclusion
In a nutshell, Veracyte Inc (VCYT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
